Synthesis andIn-vitroPharmacological Evaluation of New 5-HT1AReceptor Ligands Containing a Benzotriazinone Nucleus
作者:Ferdinando Fiorino、Beatrice Severino、Francesca De Angelis、Elisa Perissutti、Francesco Frecentese、Paola Massarelli、Giancarlo Bruni、Elga Collavoli、Vincenzo Santagada、Giuseppe Caliendo
DOI:10.1002/ardp.200700151
日期:2008.1
were selected and further evaluated for their binding affinities on D1, D2 dopaminergic and α1, α2 adrenergic receptors. The 3‐(2‐(4‐(naphthalen‐1‐yl)piperazin‐1‐yl)ethyl)benzo[d][1,2,3]triazin‐4(3H)‐one 5 with Ki = 0.000178 nM was the most active and selective derivative for the 5‐HT1A receptor with respect to other serotonin receptors and the most selective derivative compared to dopaminergic and
本文报道了新型苯并三嗪酮衍生物的5-HT1A、5-HT2A和5-HT2C受体的微波辅助合成和结合分析,以鉴定5-HT1A亚型受体的选择性配体。对反应的常规加热和微波加热进行了比较。良好的收率和较短的反应时间是我们合成路线的主要优势。选择了更多活性化合物,并进一步评估了它们对 D1、D2 多巴胺能受体和 α1、α2 肾上腺素能受体的结合亲和力。Ki = 0.000178 nM 的 3- (2- (4- (naphthalen - 1 - yl) piperazin - 1 - yl) 乙基) 苯并 [d] [1,2,3] 三嗪 - 4 (3H) -one 5 是5-HT1A 受体相对于其他血清素受体的活性和选择性最强的衍生物,与多巴胺能和肾上腺素能受体相比,选择性最强的衍生物。